Navidea Biopharmaceuticals Inc  

(Public, NYSEMKT:NAVB)   Watch this stock  
Find more results for OTC:NEOP
0.00 (0.00%)
Jul 22 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range     -
52 week 1.11 - 3.31
Open     -
Vol / Avg. 0.00/1.12M
Mkt cap 211.01M
P/E     -
Div/yield     -
EPS -0.36
Shares 150.72M
Beta 0.68
Inst. own 37%
Aug 4, 2014
Q2 2014 Navidea Biopharmaceuticals Inc Earnings Release (Estimated) Add to calendar
Jul 17, 2014
Navidea Biopharmaceuticals Inc Annual Shareholders Meeting
Jul 8, 2014
Navidea Biopharmaceuticals Inc Investor Briefing on Sentinel Lymph Node Biopsy in Head & Neck Cancers
Jun 24, 2014
Navidea Biopharmaceuticals Inc at JMP Securities Healthcare Conference
Jun 16, 2014
Navidea Biopharmaceuticals Inc sNDA Approval Conference Call
Jun 5, 2014
Navidea Biopharmaceuticals Inc at Jefferies Global Healthcare Conference - Webcast
May 22, 2014
Navidea Biopharmaceuticals Inc at BioCentury Publications BioEquity Europe Conference
May 16, 2014
Navidea Announces Restructuring of Pipeline Development Conference Call - Webcast
May 7, 2014
Q1 2014 Navidea Biopharmaceuticals Inc Earnings Release
May 7, 2014
Q1 2014 Navidea Biopharmaceuticals Inc Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -1561.66% -3776.61%
Operating margin -1488.33% -3521.10%
EBITD margin - -3363.98%
Return on average assets -129.09% -163.32%
Return on average equity - -
Employees 57 -
CDP Score - -


Suite 300, 425 Metro Place North
DUBLIN, OH 43017-1367
United States - Map
+1-614-7937500 (Phone)
+1-614-7937522 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Navidea Biopharmaceuticals, Inc. (Navidea), formerly Neoprobe Corporation, is a biopharmaceutical company focused on the development and commercialization of precision diagnostic agents. As of December 31, 2011, the Company�s radiopharmaceutical development programs included Lymphoseek (Lymphoseek, Kit for the Preparation of Technetium Tc99m for Injection), a radiopharmaceutical agent for lymph node mapping; AZD4694, an imaging agent, and RIGScan, a tumor antigen-specific targeting agent. In January 2012, the Company executed an option agreement with Alseres Pharmaceuticals, Inc. (Alseres) to license [123I]-E-IACFT Injection, also called Altropane, an Iodine-123 radiolabeled imaging agent, being developed as an aid in the diagnosis of Parkinson�s disease, movement disorders and dementia. In August 2011, the Company sold its gamma detection device line of business (the GDS Business) to Devicor Medical Products, Inc.

Officers and directors

Gordon A. Troup Independent Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Thomas H. Tulip Ph.D. President, Chief Business Officer
Age: 60
Bio & Compensation  - Reuters
Michael M. Goldberg M.D. Interim Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Brent L. Larson Chief Financial Officer, Senior Vice President, Treasurer, Secretary
Age: 49
Bio & Compensation  - Reuters
Frederick O. Cope Ph.D. SVP - Pharmaceutical Research and Clinical Development
Age: 66
Bio & Compensation  - Reuters
William J. Regan Senior Vice President - Global Regulatory Strategy
Age: 61
Bio & Compensation  - Reuters
Cornelia B. Reininger M.D., Ph.D. Senior Vice President, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Perry A. Karsen Director
Age: 59
Bio & Compensation  - Reuters
Eric K. Rowinsky M.D. Director
Age: 57
Bio & Compensation  - Reuters
Peter F Drake Ph.D. Independent Director
Age: 59
Bio & Compensation  - Reuters